Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis

Molecular Pharmacology

Volumn 77, Issue 3, 2010, Pages 416-423

  Chen, Wenjie ^a   Bai, Lang ^a   Wang, Xia ^b   Xu, Shanling ^a   Belinsky, Steven A ^a   Lin, Yong ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; DOXORUBICIN; FLICE INHIBITORY PROTEIN; PROTEIN KINASE B; PROTEIN MCL 1; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 77149128046     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.061226     Document Type: Article

References (40)

1. Arúajo AM, Mendez JC, Coelho AL, Sousa B, Barata F, Figueiredo A, Amaro T, Azevedo I, and Soares M (2009) Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer. Cancer Invest 27:391-396.
2. Ashkenazi A (2008) Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19:325-331.
3. Bai L, Chen W, Chen W, Wang X, Tang H, and Lin Y (2009) IKKbeta-mediated nuclear factor-kappaB activation attenuates smac mimetic-induced apoptosis in cancer cells. Mol Cancer Ther 8:1636-1645.
4. Brown JR and DuBois RN (2004) Cyclooxygenase as a target in lung cancer. Clin Cancer Res 10:4266s-4269s.
5. Chen S, Liu X, Yue P, Schönthal AH, Khuri FR, and Sun SY (2007a) CCAAT/ enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells. Mol Pharmacol 72:1269-1279.
6. Chen W, Wang X, Zhuang J, Zhang L, and Lin Y (2007b) Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis 28:2114-2121.
7. Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, and Schönthal AH (2008) COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer 7:38.
8. Fulda S (2009) Tumor resistance to apoptosis. Int J Cancer 124:511-515.
9. Gatenby RA, Silva AS, Gillies RJ, and Frieden BR (2009) Adaptive therapy. Cancer Res 69:4894-4903.
10. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, and Kaidi A (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30:377-386.
11. Hanada M, Feng J, and Hemmings BA (2004) Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 1697:3-16.
12. Hardy MM, Blomme EA, Lisowski A, Chinn KS, Jones A, Harmon JM, Opsahl A, Ornberg RL, and Tripp CS (2003) Selective cyclooxygenase-2 inhibition does not alter keratinocyte wound responses in the mouse epidermis after abrasion. J Pharmacol Exp Ther 304:959-967.
13. Heath-Engel HM, Chang NC, and Shore GC (2008) The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family. Oncogene 27:6419-6433.
14. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, and Takahashi T (1998) Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58:3761-3764.
15. Ju W, Wang X, Shi H, Chen W, Belinsky SA, and Lin Y (2007) A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol 71:1381-1388.
16. Kern MA, Haugg AM, Koch AF, Schilling T, Breuhahn K, Walczak H, Fleischer B, Trautwein C, Michalski C, Schulze-Bergkamen H, et al. (2006) Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 66:7059-7066.
17. Keuling AM, Felton KE, Parker AA, Akbari M, Andrew SE, and Tron VA (2009) RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One 4:e6651.
18. Kusumoto H, Rodgers QE, Boege F, Raimondi SC, and Beck WT (1996) Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Cancer Res 56:2573-2583.
19. Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, and Thorgeirsson SS (2008) E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 135:1322-1332.
20. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, and Dubinett SM (2008a) Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 66:208-217.
21. Lee YH, Suzuki YJ, Griffin AJ, and Day RM (2008b) Hepatocyte growth factor regulates cyclooxygenase-2 expression via beta-catenin, Akt, and p42/p44 MAPK in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 294:L778-L786.
22. Lin MT, Lee RC, Yang PC, Ho FM, and Kuo ML (2001) Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 276:48997-49002.
23. Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S, and Liu ZG (2000) The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol 20:6638-6645.
24. Malhi H and Gores GJ (2006) TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 25:7333-7335.
25. Malhotra S, Shafiq N, and Pandhi P (2004) COX-2 inhibitors: a CLASS act or Just VIGORously promoted. MedGenMed 6:6.
26. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, et al. (2009) A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 15:2158-2165.
27. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, and Donner DB (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401:82-85.
28. Papenfuss K, Cordier SM, and Walczak H (2008) Death receptors as targets for anti-cancer therapy. J Cell Mol Med 12:2566-2585.
29. Pop C and Salvesen GS (2009) Human caspases: activation, specificity, and regulation. J Biol Chem 284:21777-21781.
30. Rao R, Hao CM, and Breyer MD (2004) Hypertonic stress activates glycogen synthase kinase 3beta-mediated apoptosis of renal medullary interstitial cells, suppressing an NFkappaB-driven cyclooxygenase-2-dependent survival pathway. J Biol Chem 279:3949-3955.
31. Suzuki R, Yamamoto M, Saka H, Taniguchi H, Shindoh J, Tanikawa Y, Nomura F, Gonda H, Imaizumi K, Hasegawa Y, et al. (2009) A phase II study of carboplatin and paclitacel with meloxicam. Lung Cancer 63:72-76.
32. Telliez A, Furman C, Pommery N, and Hénichart JP (2006) Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity. Anticancer Agents Med Chem 6:187-208.
33. Wajant H, Gerspach J, and Pfizenmaier K (2005) Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 16:55-76.
34. Wang Q, Zhou Y, Wang X, and Evers BM (2006a) Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. Oncogene 25:43-50.
35. Wang X, Chen W, and Lin Y (2007) Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-kappaB and Akt pathways. Biochem Biophys Res Commun 355:807-812.
36. Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, Belinsky SA, and Lin Y (2008) Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther 7:1156-1163.
37. Wang X, Ju W, Renouard J, Aden J, Belinsky SA, and Lin Y (2006b) 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factorinduced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer Res 66:1089-1095.
38. Wang X and Lin Y (2008) Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 29:1275-1288.
39. Wilson TR, Johnston PG, and Longley DB (2009) Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 9:307-319.
40. Xu L, Zhang L, Yi Y, Kang HK, and Datta SK (2004) Human lupus T cells resist inactivation and escape death by up-regulating COX-2. Nat Med 10:411-415.